
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a commercial-stage biotech firm that has shown strong financial performance due to its flagship drug Brukinsa, which makes up for the majority of its revenue. The company has also expanded its portfolio with the approval of two other drugs, Beqalzi and Tevimbra, with a focus on the Chinese market. Additionally, with over 50 drugs in clinical trials, BeOne has a promising drug pipeline that could continue to drive growth in the future, especially in the competitive market of oncology therapeutics.
Bears say
BeOne Medicines is a global commercial-stage biotech company specializing in the development and production of oncology therapeutics. While the company's main product, Brukinsa, has a strong global leadership position, its other approved drugs generate most of its revenue in China. The company also has a diverse pipeline of over 50 drugs in various stages of clinical trials targeting different forms of cancer. However, ONC faces potential challenges in implementing green manufacturing processes, ensuring clinical trial integrity and diversity, and socially responsible drug pricing, which may hinder long-term growth and limit upside potential.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares